We are live on ! Find out more
Ken Griffin

Ken Griffin Citadel Advisors

AUM $618B
1-Year Est. Return 30.34%
 

Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.

This Fund
S&P 500
This Quarter Est. Return
+6.7%
1 Year Est. Return
+30.34%
3 Year Est. Return
+94.87%
5 Year Est. Return
+105.94%
10 Year Est. Return
+434.06%
AUM
$164B
AUM Growth
+$34B
Cap. Flow
+$21.1B
Cap. Flow %
12.82%
Top 10 Hldgs %
19.02%
Holding
8,908
New
1,440
Increased
3,569
Reduced
2,696
Closed
988

Sector Composition

Rank Sector Weight
1 Technology 6.22%
2 Financials 6.16%
3 Industrials 5.09%
4 Consumer Discretionary 4.89%
5 Healthcare 4.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
USA icon
7326
Liberty All-Star Equity Fund
USA
$1.88B
$84K ﹤0.01%
+13,373
New +$82K
INO icon
7327
CALL
Inovio Pharmaceuticals
INO
$105M
$83K ﹤0.01%
1,667
-125
-7% -$7.75K
BNED icon
7328
PUT
Barnes & Noble Education
BNED
$416M
$82K ﹤0.01%
+100
New +$66.1K
MNOV icon
7329
MediciNova
MNOV
$64.5M
$82K ﹤0.01%
+12,605
New +$83.6K
RETO icon
7330
ReTo Eco-Solutions
RETO
$10.9M
0
RAS
7331
DELISTED
RAIT Financial Trust
RAS
$82K ﹤0.01%
218,621
+140,688
+181% +$63.5K
INO icon
7332
PUT
Inovio Pharmaceuticals
INO
$105M
$81K ﹤0.01%
1,625
+625
+63% +$38.7K
SID icon
7333
PUT
Companhia Siderúrgica Nacional
SID
$1.18B
$81K ﹤0.01%
33,200
+4,200
+14% +$10.8K
IMGN
7334
PUT
DELISTED
Immunogen Inc
IMGN
$81K ﹤0.01%
12,600
-14,700
-54% -$90.7K
SCYX icon
7335
SCYNEXIS
SCYX
$52.2M
$80K ﹤0.01%
+431
New +$71.6K
NTBL
7336
CALL
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$80K ﹤0.01%
+323
New +$75.1K
BBG
7337
PUT
DELISTED
Bill Barrett Corp
BBG
$80K ﹤0.01%
+15,500
New +$79.3K
TLPH icon
7338
CALL
Talphera
TLPH
$62.3M
$79K ﹤0.01%
1,960
+330
+20% +$16.1K
LEE icon
7339
PUT
Lee Enterprises
LEE
$181M
$78K ﹤0.01%
+3,310
New +$77.6K
SREV
7340
PUT
DELISTED
ServiceSource International, Inc.
SREV
$78K ﹤0.01%
+25,200
New +$81K
AGC
7341
DELISTED
Advent Claymore Conv Sec & Incme
AGC
$78K ﹤0.01%
+12,987
New +$79.1K
PVLA
7342
Palvella Therapeutics
PVLA
$2.23B
$77K ﹤0.01%
+128
New +$59.5K
CCXI
7343
PUT
DELISTED
ChemoCentryx, Inc.
CCXI
$77K ﹤0.01%
+13,000
New +$89.2K
CIA icon
7344
Citizens
CIA
$201M
$76K ﹤0.01%
+10,398
New +$79.3K
CTSO icon
7345
CALL
Cytosorbents Corp
CTSO
$24.1M
$76K ﹤0.01%
11,700
-3,200
-21% -$20.4K
FGB
7346
DELISTED
First Trust Specialty Finance and Financial Opportunities Fund
FGB
$76K ﹤0.01%
+12,299
New +$80.5K
KG
7347
PUT
Kestrel Group
KG
$61M
$76K ﹤0.01%
575
-4,275
-88% -$640K
RIGL icon
7348
PUT
Rigel Pharmaceuticals
RIGL
$784M
$76K ﹤0.01%
1,960
+750
+62% +$28.5K
TTI icon
7349
TETRA Technologies
TTI
$1.26B
$76K ﹤0.01%
17,730
-540,765
-97% -$1.86M
HK
7350
CALL
DELISTED
Halcon Resources Corporation
HK
$76K ﹤0.01%
+10,100
New +$69.3K

Similar funds

Ken Griffin's Q4 2017 Portfolio in Review

As of Q4 2017, Ken Griffin held 8,908 positions worth $164B, up 26% from $130B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Ken Griffin deployed $21.1B of net new capital in Q4 2017, opening 1,440 new positions and adding to 3,569 existing holdings. Its largest new stake was Celgene Corp: 3,708,916 shares worth $387M.

By sector, the portfolio is most concentrated in Technology at 6.2% of assets, down from 7.2% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Goldman Sachs, an estimated $441M trimmed.

  • Ken Griffin's largest Q4 2017 buy was Celgene Corp: 3,708,916 shares worth $387M.
  • Ken Griffin added most to State Street SPDR S&P 500 ETF Trust in Q4 2017, an estimated $1.16B increase.
  • Ken Griffin's biggest Q4 2017 reduction was Goldman Sachs, cutting an estimated $441M.
  • Ken Griffin fully exited CR Bard Inc. in Q4 2017, selling an estimated $209M.
  • Ken Griffin's ten largest holdings make up 19% of its $164B portfolio in Q4 2017.
  • Ken Griffin opened 1,440 new positions and closed 988 in Q4 2017.
  • Ken Griffin's portfolio value rose 26% quarter-over-quarter to $164B.

Based on Citadel Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.